Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORshock lower blood pressure target strategy in cardiogenic shock after acute myocardial infarction
NL-OMON58897Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of norepinephrine in cardiogenic shock and myocardial infarction (MI) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite of all-cause mortality and severe renal failure requiring renal replacement therapy. Started Feb 2024; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
cardiogenic shockmyocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON58897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58897.